[go: up one dir, main page]

JP2007516259A - 活性剤との混合相共結晶の調製方法 - Google Patents

活性剤との混合相共結晶の調製方法 Download PDF

Info

Publication number
JP2007516259A
JP2007516259A JP2006544038A JP2006544038A JP2007516259A JP 2007516259 A JP2007516259 A JP 2007516259A JP 2006544038 A JP2006544038 A JP 2006544038A JP 2006544038 A JP2006544038 A JP 2006544038A JP 2007516259 A JP2007516259 A JP 2007516259A
Authority
JP
Japan
Prior art keywords
peg
acid
oil
glyceryl
sorbitan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006544038A
Other languages
English (en)
Japanese (ja)
Inventor
ゴールドマン、デイヴィッド
Original Assignee
メッドクリスタルフォームズ、エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メッドクリスタルフォームズ、エルエルシー filed Critical メッドクリスタルフォームズ、エルエルシー
Publication of JP2007516259A publication Critical patent/JP2007516259A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2006544038A 2003-12-09 2004-12-09 活性剤との混合相共結晶の調製方法 Pending JP2007516259A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52823203P 2003-12-09 2003-12-09
US55986204P 2004-04-06 2004-04-06
PCT/US2004/041500 WO2005055983A2 (fr) 2003-12-09 2004-12-09 Procede de preparation de cocristaux a phase mixte avec des agents actifs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011149502A Division JP2011256175A (ja) 2003-12-09 2011-07-05 活性剤との混合相共結晶の調製方法

Publications (1)

Publication Number Publication Date
JP2007516259A true JP2007516259A (ja) 2007-06-21

Family

ID=34681550

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006544038A Pending JP2007516259A (ja) 2003-12-09 2004-12-09 活性剤との混合相共結晶の調製方法
JP2011149502A Pending JP2011256175A (ja) 2003-12-09 2011-07-05 活性剤との混合相共結晶の調製方法
JP2014182177A Pending JP2015091773A (ja) 2003-12-09 2014-09-08 活性剤との混合相共結晶の調製方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011149502A Pending JP2011256175A (ja) 2003-12-09 2011-07-05 活性剤との混合相共結晶の調製方法
JP2014182177A Pending JP2015091773A (ja) 2003-12-09 2014-09-08 活性剤との混合相共結晶の調製方法

Country Status (5)

Country Link
US (1) US9682043B2 (fr)
EP (1) EP1727520A2 (fr)
JP (3) JP2007516259A (fr)
CA (1) CA2548281C (fr)
WO (1) WO2005055983A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520235A (ja) * 2012-06-18 2015-07-16 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． プロゲステロン製剤
WO2017116190A1 (fr) * 2015-12-31 2017-07-06 Yuyu Pharma, Inc. Composition pharmaceutique comprenant du dutastéride et du monolaurate de propylène glycol, et son procédé de préparation
JP2018510180A (ja) * 2015-03-31 2018-04-12 ホビオネ サイエンティア リミテッド 粒子の連続製造方法
JP2022101588A (ja) * 2016-08-19 2022-07-06 セルジュヌ アンテルナシオナル ドゥジエム ソシエテ ア レスポンサビリテ リミティー マリゾミブのモルフィック形態およびその使用
JP2022109243A (ja) * 2021-01-14 2022-07-27 デボン エルエス カンパニー，リミテッド メシル酸ナファモスタットの共結晶多形及びその製造方法

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
EP1494998A2 (fr) 2002-03-01 2005-01-12 University Of South Florida Phases solides multicomposants contentant au moins un principe pharmaceutiquement actif
EP1483283A4 (fr) 2002-03-13 2007-04-11 Signum Biosciences Inc Modulation de la methylation de proteines et du phosphate des phosphoproteines
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2004080461A2 (fr) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Compositions pharmaceutiques stables de desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
CA2538237A1 (fr) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Formulations d'aerosol pour administrer de la dihydroergotamine a la circulation systemique par voie pulmonaire
EP2489659B1 (fr) 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l´ATP
KR20070052760A (ko) * 2004-08-06 2007-05-22 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 페노피브레이트 제제 및 관련된 치료방법
WO2007130713A1 (fr) * 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Nouvelles formules de fénofibrate et méthodes de traitement correspondantes
US20090030077A1 (en) * 2004-08-06 2009-01-29 Transform Pharmaceuticals Inc. Novel Fenofibrate Formulations and Related Methods of Treatment
WO2006024930A1 (fr) * 2004-09-01 2006-03-09 Pharmacia & Upjohn Company Llc Nouveaux co-cristaux entre polyethylene glycols et 5-phenylpyrazolyl-1-benzenesulfonamides
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1843734A4 (fr) 2005-02-03 2008-09-10 Signum Biosciences Inc Compositions et procedes pour l'amelioration de la fonction cognitive
RS60205B1 (sr) 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
WO2007092779A2 (fr) * 2006-02-03 2007-08-16 Dr. Reddy's Laboratories Ltd. Co-cristaux d'aripiprazole
US9386770B2 (en) * 2006-06-13 2016-07-12 Phibro Animal Health Corp. Use of predissolved pristinamycin-type and polyether ionophore type antimicrobial agents in the production of ethanol
HUE026884T2 (en) 2007-02-11 2016-08-29 Map Pharmaceuticals Inc DHE is a therapeutic method of administration for the rapid relief of migraine while minimizing side effects
EP1998749A1 (fr) * 2007-04-13 2008-12-10 Helm AG Procede de preparation d'adsorbats de perindopril-tert-butylamine
EP2044934A1 (fr) * 2007-10-01 2009-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dispersion de particules de protéines poloxamères, les méthodes de production et l'emploi de cette dispersion
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
WO2009132051A1 (fr) * 2008-04-21 2009-10-29 Signum Biosciences, Inc. Composés, compositions et procédés pour préparer ceux-ci
US9023891B2 (en) 2008-05-29 2015-05-05 Nevada Naturals, Inc. Synergistic antimicrobial agents
US8258155B2 (en) * 2008-06-30 2012-09-04 Mutual Pharmaceutical Company, Inc. Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof
EA018905B1 (ru) * 2008-07-25 2013-11-29 Бионевия Фармасьютикалс, Инк. Новый бетаиновый сокристалл эпалрестата
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
LT2326632T (lt) 2008-09-06 2017-09-25 Bionevia Pharmaceuticals, Inc. Naujas epalrestato cholino kokristalas
EP2177215A1 (fr) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux de tramadol et NSAID
PT2408750E (pt) 2009-03-20 2015-10-15 Vertex Pharma Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística
US20120258170A1 (en) * 2009-05-20 2012-10-11 Nutracryst Therapeutics Private Limited Pharmaceutical co-crystals of quercetin
US20120129923A1 (en) * 2009-05-20 2012-05-24 Nutracryst Therapeutics Private Limited Pharmaceutical co-crystals of quercetin
US8545892B2 (en) * 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
UA110199C2 (xx) * 2009-10-27 2015-12-10 Lupin Ltd Тверда дисперсія рифаксиміну
PL2501234T3 (pl) 2009-11-20 2018-01-31 Tonix Pharma Holdings Ltd Sposoby i kompozycje stosowane w leczeniu dolegliwości związanych z zespołem stresu pourazowego z użyciem cyklobenzapryny
TWI478730B (zh) * 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
US8871793B2 (en) 2009-12-23 2014-10-28 Nuformix Limited Metaxalone cocrystals
CN102933205B (zh) * 2010-04-28 2014-08-13 诺弗米克斯有限公司 西洛他唑共晶和组合物
CN103269587A (zh) * 2010-06-03 2013-08-28 萨利克斯药品有限公司 利福昔明的新形式及其用途
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
HRP20151321T1 (hr) 2011-01-20 2016-01-29 Bionevia Pharmaceuticals Inc. Epalrestat ili njegov derivat u oblicima s prilagođenim otpuštanjem te postupci uporabe istih
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
MX352278B (es) 2011-06-23 2017-11-16 Procter & Gamble Proceso de formacion de cristales para usar en una composicion para el cuidado personal.
WO2013009997A1 (fr) 2011-07-12 2013-01-17 Burn-Off, Llc Composition et procédé d'utilisation de la composition, efficace pour minimiser les effets nocifs associés aux individus souffrant d'une intoxication alcoolique
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
US20130224293A1 (en) 2012-02-27 2013-08-29 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
CN104379130B (zh) 2012-03-30 2018-01-02 诺弗米克斯有限公司 曲尼司特组合物和共结晶体
BR112014027814A2 (pt) * 2012-05-07 2017-06-27 Nevada Naturals Inc agentes sinérgicos antimicrobianos.
CN104640537A (zh) * 2012-09-18 2015-05-20 麦克内尔-Ppc股份有限公司 用于口服剂型的低熔点丙酸衍生物粒子
GB201222287D0 (en) 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
AU2014233277B2 (en) 2013-03-15 2019-04-04 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US9394327B1 (en) * 2013-03-15 2016-07-19 The Trustees Of California State University Nucleoside crystals, crystal nucleation and growth control with antifreeze proteins
EP3080141A1 (fr) * 2013-12-12 2016-10-19 Basf Se Forme solide d'acétate d'abiratérone
CN103951634B (zh) * 2014-05-07 2016-06-08 浙江东亚药业股份有限公司 一种依帕司他结晶盐水合物和羟基哌啶共晶物及其制备方法和应用
FR3023177B1 (fr) * 2014-07-04 2016-08-12 Centre Nat De La Rech Scient (C N R S) Procede de preparation de co-cristaux par evaporation flash
AU2015317336B2 (en) 2014-09-18 2021-01-21 Tonix Pharma Holdings Limited Eutectic formulations of Cyclobenzaprine hydrochloride
MX370450B (es) 2014-10-07 2019-12-13 Vertex Pharma Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
BR112017014953A2 (pt) 2015-01-12 2018-03-13 Nano Pharmaceutical Laboratories Llc microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos
BR112017027285A2 (pt) * 2015-06-19 2018-09-11 Syn Nat Products Entpr Llc ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
US20170035781A1 (en) 2015-06-22 2017-02-09 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP6929234B2 (ja) * 2015-06-25 2021-09-01 シン−ナット プロダクツ エンタープライズ エルエルシー 医薬共結晶組成物及びその用途
WO2017053938A1 (fr) * 2015-09-24 2017-03-30 Pain Therapeutics, Inc. Sels cristallins de naloxone et de naltrexone
EP3352822B1 (fr) 2015-09-24 2022-07-27 Pain Therapeutics, Inc. Co-cristaux de naloxone et de naltrexone
EP3168211A1 (fr) 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Co-cristaux pharmaceutiques de niclosamide
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) * 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US9877942B1 (en) * 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
WO2019030158A1 (fr) * 2017-08-07 2019-02-14 Enantia, S.L. Co-cristal de 2-[(1r,6r)-6-isopropényl-3-méthylcyclohex-2-en-1-yl]-5-pentylbenzène-1,3-diol
EP3668501A4 (fr) 2017-08-17 2021-03-17 Zi-Qiang Gu Agents anti-parkinson de type sels de pamoate de monoamine, leur procédé de préparation et d'utilisation
US11826321B2 (en) 2017-12-11 2023-11-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2019160805A1 (fr) * 2018-02-13 2019-08-22 Transgenex Nanobiotech, Inc. Nouvelles formes cristallines d'actinomycine d pour le traitement du cancer
KR102691673B1 (ko) 2018-02-21 2024-08-06 알콘 인코포레이티드 지질-기재 안과용 에멀션
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
GB2581502A (en) * 2019-02-19 2020-08-26 Univ Bristol Solidification or crystallisation method
CN119868330A (zh) 2019-03-01 2025-04-25 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
CN113956193A (zh) * 2020-06-12 2022-01-21 深圳市水槟榔生物科技有限公司 一种槟榔碱提取物的制备方法
CN114105888B (zh) * 2020-08-25 2023-12-01 天津大学 丙基硫氧嘧啶与具有抗氧化活性的营养素小分子的共晶及其制备方法
KR102522788B1 (ko) * 2021-01-28 2023-04-18 (주)아이엠디팜 카모스타트 및 니클로사마이드를 포함하는 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
US20220168239A1 (en) * 2021-02-22 2022-06-02 Gholamhossein Yousefi Preparation of soluble form of curcumin
JP2024513388A (ja) * 2021-03-31 2024-03-25 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 複合薬物粒子及びその使用
CN113354596B (zh) * 2021-06-01 2022-11-29 天津大学 依帕司他-二甲双胍盐丙酮溶剂化物及制备方法和应用
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN114948959B (zh) * 2022-05-18 2023-11-07 中山大学 一种调控肿瘤乳酸代谢的纳米药物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63240936A (ja) * 1986-12-31 1988-10-06 センター・ナショナル・ド・ラ・リセルシェ・サイエンティフィク 超微粒子状物質の分散コロイド系の製造方法
JP2002506876A (ja) * 1998-03-18 2002-03-05 ユニバーシティ テクノロジー コーポレーション 非晶質ポリマーを含む持続放出性組成物
WO2002055059A2 (fr) * 2000-12-22 2002-07-18 Baxter Int Preparation de suspensions de particules submicroniques
JP2002356419A (ja) * 2001-03-29 2002-12-13 Takeda Chem Ind Ltd 微粒薬物の製造法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384980A (en) * 1977-07-19 1983-05-24 Allied Corporation Co-crystallized acetylenic compounds
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
IE980115A1 (en) 1998-02-16 2000-02-09 Biovail Internat Ltd Solubilizing delivery systems and method of manufacture
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6596206B2 (en) * 2001-03-30 2003-07-22 Picoliter Inc. Generation of pharmaceutical agent particles using focused acoustic energy
US20030031721A1 (en) 2001-07-31 2003-02-13 Bogue Beuford Arlie Micro- and nano-particulate drugs and methods of making thereof
CA2458889C (fr) * 2001-08-29 2011-06-21 Dow Global Technologies Inc. Procede de precipitation de particules medicamenteuses
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030166509A1 (en) * 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
EP1494998A2 (fr) * 2002-03-01 2005-01-12 University Of South Florida Phases solides multicomposants contentant au moins un principe pharmaceutiquement actif
JP2005535602A (ja) 2002-05-31 2005-11-24 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 新規コナゾール結晶形及び関連方法、医薬組成物及び方法
US20040185110A1 (en) * 2002-11-08 2004-09-23 Ronald Harland Formulations of low solubility bioactive agents and processes for making the same
JP4923182B2 (ja) * 2003-02-28 2012-04-25 マクニール−ピーピーシー・インコーポレーテツド セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
DE10312763A1 (de) * 2003-03-21 2004-09-30 IFAC Institut für angewandte Colloidtechnologie GmbH & Co. KG Verfahren zur Herstellung einer SLN-Dispersion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63240936A (ja) * 1986-12-31 1988-10-06 センター・ナショナル・ド・ラ・リセルシェ・サイエンティフィク 超微粒子状物質の分散コロイド系の製造方法
JP2002506876A (ja) * 1998-03-18 2002-03-05 ユニバーシティ テクノロジー コーポレーション 非晶質ポリマーを含む持続放出性組成物
WO2002055059A2 (fr) * 2000-12-22 2002-07-18 Baxter Int Preparation de suspensions de particules submicroniques
JP2002356419A (ja) * 2001-03-29 2002-12-13 Takeda Chem Ind Ltd 微粒薬物の製造法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520235A (ja) * 2012-06-18 2015-07-16 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． プロゲステロン製剤
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US10639375B2 (en) 2012-06-18 2020-05-05 Therapeuticsmd, Inc. Progesterone formulations
JP2018510180A (ja) * 2015-03-31 2018-04-12 ホビオネ サイエンティア リミテッド 粒子の連続製造方法
WO2017116190A1 (fr) * 2015-12-31 2017-07-06 Yuyu Pharma, Inc. Composition pharmaceutique comprenant du dutastéride et du monolaurate de propylène glycol, et son procédé de préparation
US10561619B2 (en) 2015-12-31 2020-02-18 Yuyu Pharma, Inc. Pharmaceutical composition comprising dutasteride and propylene glycol monolaurate and preparation method of the same
JP2022101588A (ja) * 2016-08-19 2022-07-06 セルジュヌ アンテルナシオナル ドゥジエム ソシエテ ア レスポンサビリテ リミティー マリゾミブのモルフィック形態およびその使用
JP2022109243A (ja) * 2021-01-14 2022-07-27 デボン エルエス カンパニー，リミテッド メシル酸ナファモスタットの共結晶多形及びその製造方法

Also Published As

Publication number Publication date
US9682043B2 (en) 2017-06-20
EP1727520A2 (fr) 2006-12-06
US20050181041A1 (en) 2005-08-18
CA2548281C (fr) 2013-11-12
JP2011256175A (ja) 2011-12-22
WO2005055983A3 (fr) 2007-03-01
WO2005055983A2 (fr) 2005-06-23
JP2015091773A (ja) 2015-05-14
CA2548281A1 (fr) 2005-06-23

Similar Documents

Publication Publication Date Title
JP2007516259A (ja) 活性剤との混合相共結晶の調製方法
US7122198B1 (en) Fast dissolving composition with prolonged sweet taste
KR100689686B1 (ko) 활성 성분의 흡수 강화를 위한 활성을 갖는 화합물을함유하는 약학적 조성물
US5446070A (en) Compositions and methods for topical administration of pharmaceutically active agents
US5719197A (en) Compositions and methods for topical administration of pharmaceutically active agents
CN101005828B (zh) 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
DE69833000T2 (de) Bio-klebemittelzusammensetzungen
ES2596809T3 (es) Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
US6638528B1 (en) Compositions and methods to effect the release profile in the transdermal administration of active agents
KR20010015631A (ko) 생체 유착성 조성물 및 활성제의 국소 투여 방법
HK1101554B (en) Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
MXPA00002983A (en) Bioadhesive compositions and methods for topical administration of active agents

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110330

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025